Expression of the transcription factor PAX5 in childhood acute leukemic cells.
- Author:
Bei ZHANG
1
;
Li-Jun TIE
;
Qi-Dong YE
;
Long-Jun GU
;
Jing-Yan TANG
;
Xiang-Liang YUAN
;
Li-Song SHEN
Author Information
1. Laboratory Diagnostic Center, Xinhua Hospital and Shanghai Children's Medical Center, Shanghai Second Medical University, Shanghai 200127, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Antigens, CD19;
biosynthesis;
genetics;
Cell Line, Tumor;
Child;
Child, Preschool;
Female;
Humans;
Infant;
Male;
PAX5 Transcription Factor;
biosynthesis;
genetics;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
metabolism;
pathology;
RNA, Messenger;
biosynthesis;
genetics;
Transcription Factors;
biosynthesis;
genetics
- From:
Journal of Experimental Hematology
2006;14(1):6-10
- CountryChina
- Language:Chinese
-
Abstract:
To investigate transcription factor PAX5 expression characteristics in childhood acute leukemic cells, expression levels of PAX5 and CD19 mRNA in 6 hematological tumor cell lines and bone marrow cells of 6 normal children, 58 de novo patients and 4 relapse acute leukemic children, including 39 cases of B-ALL, 10 cases of T-ALL and 13 cases of AML, were detected by a real-time RT-PCR. The results showed that PAX5 and CD19 mRNA expression levels were 2.35% and 2.52% in Namalwa (B-cell lines) respectively, but almost not detectable in other T- and myeloid cell lines. Among clinical samples, expression of PAX5 mRNA in B-ALL was significantly higher than that in T-ALL and AML (P = 0.029 and P = 0.013 respectively). PAX5 expression was significantly lower in T-ALL and AML than that in normal controls. The difference of PAX5 mRNA expression levels between T-ALL and AML was not significant. Individual difference of PAX5 mRNA expression levels in children with B-ALL was great. Moreover, PAX5 mRNA expressions in de novo and relapse patients with B-ALL were significantly higher than those in remission (P = 0.011 and P = 0.006 respectively). As binding sites for B-cell specific activator protein have been identified in the promoter regions of CD19, the study found that in B-ALL, there was clear correlation between the expression levels of PAX5 and CD19, which was also studied by real-time RT-PCR. It is concluded that PAX5 transcripts are readily detectable and quantifiable in clinical materials with B-ALL by real-time RT-PCR. The strong PAX5 mRNA expression in some B-ALL can be considered to be particularly interesting for further analysis.
